AI-driven discovery, EHR-based real-world evidence, and synthetic patient modeling are rapidly reshaping drug repurposing, reducing development timelines, expanding therapeutic applications, and ...

In today’s ACT Brief, we look at what’s fueling rapid growth in CNS and autoimmune research, why former FDA leaders are ...

Chen: Yes, obesity is experiencing accelerated growth over the last couple of years. According to our sister product Evaluate ...

In their NEJM commentary, the former FDA heads stated, “We are deeply concerned by sweeping new FDA assertions about vaccine safety and proposals that would undermine a regulatory model designed to ...

In today’s ACT Brief, we look at new insights on strategy-driven clinical development, fresh survey data revealing persistent ...

For industry-sponsored trials in autoimmune inflammation therapeutic areas, the dominating indications include atopic ...

ICON’s June 2025 survey of more than 100 investigators and site leaders reveals persistent bottlenecks in study startup driven by contract and budget delays, slow activation timelines, and ...

Examine the rise of personalized and biomarker-driven therapies, the logistical challenges of rare patient populations, and ...

Investigate how sponsors are responding to rapid growth in obesity drug development, including strategies for manufacturing, supply chain optimization, dosing innovations, and combination therapies to ...

The FDA has launched a secure, GovCloud-based agentic AI system to support regulatory workflows across review divisions, ...

A new global Tufts CSDD survey of 387 investigative site professionals reveals broad experience with digital and decentralized trial tools, growing site-driven technology investments, and strong ...

A new global Tufts CSDD survey of 387 investigative site professionals reveals broad experience with digital and decentralized trial tools, growing site-driven technology investments, and strong ...